Skip to content

Paul E. Holtzheimer

3 papers in the library · 81 citations · publishing 2018-2024

Papers

Sort Most recent Most cited

Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence.

American Journal of Psychiatry December 1, 2024 Lauren M. Sippel, Jessica L. Hamblen, Benjamin Kelmendi et al. 11 citations

Posttraumatic stress disorder (PTSD) is a highly prevalent psychiatric disorder that can become chronic and debilitating when left untreated. The most commonly recommended first-line treatments for PTSD among adults are individual trauma-focused psychotherapies. Other evidence-based treatments include specific antidepressant medications and non-trauma-focused psychotherapies. Despite the...

DOI: 10.1176/appi.ajp.20230950 (opens in new tab) Full text (opens in new tab) Behavioral psychotherapy Cognitive psychotherapy Drug psychotherapy combination Evidence-based treatment +6

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

The British Journal of Psychiatry July 14, 2023 Colleen Loo, N. Glozier, David Barton et al. 70 citations

Background Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed. Aims To assess the acute efficacy and safety of a 4-week course of subcutaneous racemic ketamine in participants with TRD. Trial registration: ACTRN12616001096448 at www.anzctr.org.au. Method This phase 3,...

Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.

Biological Psychiatry September 20, 2018 Samuel T. Wilkinson, Paul E. Holtzheimer, Shan Gao et al.

Until recently, therapeutic development in psychiatry was targeted solely toward symptom reduction. While this is a worthwhile goal, it has yielded little progress in improved therapeutics in the last several decades in the field of mood disorders. Recent advancements in our understanding of pathophysiology suggests that an impairment of neuroplasticity may be a critical part of the development...